How much does Farxiga cost with Medicare in New Jersey?

Farxiga (dapagliflozin) is an SGLT2 inhibitor made by AstraZeneca and used for type 2 diabetes, heart failure and chronic kidney disease. In New Jersey it reached 44,289 Part D members and 7,485 prescribers in 2024. The big question for 2027 is whether your plan prefers brand Farxiga or the new generic.

Farxiga under Medicare Part D: 2026 price, generic approval and New Jersey use

Farxiga	Amount
New Jersey Part D members who filled Farxiga (2024)	44,289
New Jersey gross cost per 30-day fill (2024)	$536.87
New Jersey patient share per 30-day fill (2024)	$30.12
Medicare negotiated price, 30 days (2026)	$178.50
Below the 2023 list price of $556	68%
First generic dapagliflozin approvals	April 2026
Farxiga alone for a year, standard design (2026)	$996.75
Most common tier on renewing Part D plans for 2027 (national)	Tier 3 (2,232 of 4,748 plans)

Source: CMS fact sheet: negotiated prices for initial price applicability year 2026.

Brand Farxiga or generic dapagliflozin in 2027

FDA announced on April 7, 2026 that it had approved the first generic versions of Farxiga tablets for several companies; its first generic list shows 15 single-ingredient dapagliflozin applicants dated April 6, 2026, plus generic versions of the dapagliflozin and metformin combination. FDA tells patients to contact manufacturers about availability.

CMS has not listed Farxiga as removed from the negotiation program as of October 2026; a drug leaves only after a generic is approved and marketed, and CMS publishes that determination. Until then the brand keeps its negotiated price. On your 2027 plan, look for both names, brand Farxiga and dapagliflozin, and compare tiers.

How the 2026 price came about

CMS says 994,000 people with Part D used Farxiga in 2023, with $4.3 billion in gross costs. The negotiated $178.50 sits 68% below the $556 list price. Nationally, average gross spending per Farxiga claim went from $997.75 in 2025 to $328.97 in early 2026.

Worked example on a standard plan

Take the $615 deductible and 25% coinsurance from Medicare.gov. Your first three fills are $178.50 each, the April fill is $104.25, and the last 8 fills cost $44.63. That is $996.75 for 2026, well below the $2,100 cap. In 2027 the deductible can reach $700, which puts the same year near $1,060.50.

A generic on a lower tier, or a plan with a $0 drug deductible, would cut that further. Ask before you assume the brand is your only option.

What does not work with Medicare, and what does

The Farxiga savings card is not available to anyone enrolled in Medicare Part D, even paying as a cash customer. Extra Help is: 2026 limits are $23,940 income and $18,090 resources for one person, with brand copays of no more than $14.40 in 2027. The Medicare Prescription Payment Plan can also turn the deductible months into smaller monthly bills. New Jersey residents who qualify for PAAD pay $7 for a covered brand prescription and $5 for a generic, so the generic saves $24 over twelve fills even there.

Farxiga in New Jersey, and on 2027 drug lists

Statewide, New Jersey Part D members filled Farxiga about three times for every four Jardiance fills. Pharmacies dispensed 350,982 month-equivalents in 2024, billed at $188,431,614; enrollees covered $10,572,337 themselves, close to $238.71 apiece.

The generic is already showing up in plan design. For 2027, 2,368 of the 4,748 renewing Part D plans nationwide put dapagliflozin on a lower tier than in 2026, the largest shift of any drug on these pages, while 1,613 added step therapy, per CMS formulary files.

The April 2026 FDA list names the companies cleared to make generic dapagliflozin, among them Teva, Sandoz, Zydus, Cipla, Lupin, Aurobindo, Biocon, Alembic, Alkem, Macleods, Ajanta and Micro Labs. The same list adds generic versions of Xigduo XR (dapagliflozin with extended-release metformin) and of Qtern (dapagliflozin with saxagliptin), so if you take a combination tablet, ask about that exact product rather than plain dapagliflozin.

Prescribed for kidney disease?

If a kidney specialist started you on Farxiga for chronic kidney disease rather than for diabetes, say so at the pharmacy counter. Generic labels can list fewer uses than the brand label, and the April 2026 FDA notice described the newly approved generics in terms of glycemic control and heart failure hospitalization in type 2 diabetes. Your nephrologist and pharmacist can confirm whether substituting the generic suits your diagnosis, and your plan can tell you whether brand Farxiga needs an exception.

Related questions

Sources

1. CMS Medicare Part D Prescribers by Geography and Drug, 2024 (New Jersey) Centers for Medicare & Medicaid Services
2. CMS fact sheet: negotiated prices for initial price applicability year 2026 Centers for Medicare & Medicaid Services
3. CMS: Selected drugs and negotiated prices Centers for Medicare & Medicaid Services
4. CMS Medicare Quarterly Part D Spending by Drug Centers for Medicare & Medicaid Services
5. Medicare.gov: How much does Medicare drug coverage cost? Centers for Medicare & Medicaid Services
6. FDA: FDA approves first generic dapagliflozin tablets (April 7, 2026) U.S. Food and Drug Administration
7. FDA: First Generic Drug Approvals (2026) U.S. Food and Drug Administration
8. AstraZeneca: Farxiga savings and support AstraZeneca
9. Medicare.gov: Help with drug costs (Extra Help) Centers for Medicare & Medicaid Services
10. CMS Monthly Prescription Drug Plan Formulary and Pharmacy Network Information (CY2026 and CY2027 basic drugs formulary), with the CMS 2027 plan crosswalk Centers for Medicare & Medicaid Services
11. New Jersey Division of Aging Services: Pharmaceutical Assistance to the Aged and Disabled (PAAD) New Jersey Department of Human Services, Division of Aging Services

Please note: We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options.Garden State Medicare Solutions is not connected with or endorsed by the United States government or the federal Medicare program. Medicare has neither endorsed nor reviewed this information.